Observational Study for Assessing Treatment and Outcome of Patients With Primary Brain Tumours Using cIMPACT-NOW and 2021 WHO Classification
Recruiting
Observational Study
Glioma
Glioneuronal Tumor
Choroid Plexus Tumor
Pineal Tumors
Germ Cell Tumor
Tumor of the Sellar Region
Diffuse Midline Glioma, H3 K27M-Mutant
Ependymoma
Embryonal Tumor
Pineal Tumor
Hemangiopericytoma
Hemangioblastoma
Melanocytic Tumor of CNS
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,650 (estimated)
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC · Research network
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Every new classification depends on its prognostic power and on the type of treatment given. With the rapid evolution of diagnostic methods and the advance in new treatments, there is much less reliable information available on how patients with newly defined brain tumour entities should be treated and what to expect from the current treatments.
The goal is to determine whether the new 2021 WHO c…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
* Age ≥ legal age of consent
* Newly diagnosed or recurrent primary brain tumours within one of the 17 cohorts of interest
* Archival tumour tissue from primary tumour available at the site. Representative tissue from first surgery is preferred, but tissue from surgery for recurrence is allowed. Exc…
Contacts